Heraeus Medical GMBH v. Esschem Inc
927 F.3d 727
3rd Cir.2019Background
- Heraeus, a German maker of Palacos bone cement, developed secret specifications for copolymers R262/R263 used in its product.
- Biomet, a competitor, began selling a nearly identical cement after acquiring a distributor that had access to Heraeus’ secrets; Biomet purchased copolymers from Esschem, a Pennsylvania manufacturer.
- Heraeus obtained e‑mails from Esschem–Biomet communications by March 2011 and took a Biomet deposition in December 2011; those materials showed Biomet employees discussing copolymer specifications with Esschem.
- Heraeus sued Esschem in September 2014 under the Pennsylvania Uniform Trade Secrets Act (PUTSA) and related common‑law claims; Esschem moved for summary judgment asserting statutes of limitations defenses.
- The district court held PUTSA claims time‑barred, concluding discovery occurred by January–March 2011 and that continuing misappropriation constitutes a single claim; Heraeus appealed.
- The Third Circuit held that (1) limitations began by March 2011 (so earlier misappropriations are time‑barred) but (2) PUTSA follows Pennsylvania’s separate‑accrual rule for continuing misappropriations, so uses within three years of filing may still be sued.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| When did PUTSA limitations begin to run? | Heraeus: did not discover Esschem’s scienter until Dec 2011 deposition, so suit filed Sept 2014 was timely. | Esschem: Heraeus had necessary discovery by 2005–2011 (emails by Mar 2011), so claim is time‑barred. | Limitations began by March 2011; claims for acts before March 2011 are time‑barred. |
| Are continuing misappropriations a single claim or separately accruing violations under PUTSA? | Heraeus: PUTSA omitted UTSA’s single‑claim sentence, so Pennsylvania intended separate accrual — each wrongful use within 3 years gives a new claim. | Esschem: separate accrual would nullify the statute and let plaintiffs recover for old acts whenever a new act occurs. | PUTSA follows separate‑accrual rule; each distinct wrongful use within the 3‑year window accrues a separate cause of action. |
| Does separate accrual equate to the "continuing violation doctrine" that revives old claims? | Heraeus: separate accrual permits suits for uses occurring within limitations; it does not revive time‑barred older acts. | Esschem: conflated separate accrual with continuing‑violation doctrine to argue unfair revival of old claims. | Court: distinguished doctrines; separate accrual does not eliminate the limitations period or revive stale claims. |
| Did Heraeus plead discrete claims for each new use or otherwise forfeit separate‑accrual relief? | Heraeus: PUTSA claim alleges continuing use; separate accrual applies to wrongful uses (manufacturing process), not merely sales. | Esschem: Heraeus failed to assert distinct claims per batch; ongoing sales are not continuing misappropriation. | Court: PUTSA’s definition of "use" covers ongoing employment in manufacturing; continuing use suffices and acts within 3 years are actionable. |
Key Cases Cited
- Merck & Co. v. Reynolds, 559 U.S. 633 (2010) (scienter can be an element a plaintiff must discover under a discovery rule)
- Klehr v. A.O. Smith Corp., 521 U.S. 179 (1997) (separate accrual rule: each new overt act generally restarts the limitations period but does not permit recovery for old acts)
- Nat'l R.R. Passenger Corp. v. Morgan, 536 U.S. 101 (2002) (distinguishing continuing violation doctrine and limitations accrual rules)
- Petrella v. Metro-Goldwyn-Mayer, Inc., 572 U.S. 663 (2014) (warning against conflating separate‑accrual and continuing‑violation doctrines)
- Monolith Portland Midwest Co. v. Kaiser Aluminum & Chem. Corp., 407 F.2d 288 (9th Cir. 1969) (property view: each use of a trade secret is a new wrong)
- Davis v. Wells Fargo, 824 F.3d 333 (3d Cir. 2016) (limitations period generally begins when injury is sustained; discusses discovery rule)